secwatch.observer — SEC 8-K summary
======================================

Issuer:     Artiva Biotherapeutics, Inc. (ARTV)
CIK:        0001817241
Form:       8-K
Filed at:   2025-01-29T23:59:59+00:00
Accession:  0000950170-25-010481
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artiva appoints Daniel Baker to board; forms Clinical Strategy Committee
------------------------------------------------------------------------

- Daniel Baker, Ph.D. appointed as Class I director effective Jan 28, 2025; term expires at 2025 annual meeting.
- Baker also named to Clinical Strategy Committee; Laura Bessen, Brian Daniels, Laural Stoppel appointed as members; Diego Miralles as chair.
- Baker receives $40K annual board retainer and initial option for 27,500 shares; one-third vested immediately, remainder over two years.
- Clinical Strategy Committee members get $7,500 annual retainer; chair receives $15,000.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817241/000095017025010481/0000950170-25-010481-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817241/000095017025010481/artv-20250128.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-010481

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer